Tonix Pharmaceuticals (TNXP) Stock Is Up 115% This Week: What's Going On?

Tonix Pharmaceuticals Holding Corp TNXP shares have surged 115% to $16.85 since Monday's open, driven by a series of key business updates this week.

What To Know: Tonix this week announced data regarding its fibromyalgia treatment, TNX-102 SL, presenting Phase 3 data at the 7th International Congress on Controversies in Fibromyalgia.

The study showed that the sublingual formulation demonstrated a statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain reduced pain. The U.S. FDA has set an August 15, 2025, Prescription Drug User Fee Act (PDUFA) goal date for potential marketing approval.

Tonix also announced the appointment of Siobhan Fogarty as Chief Technical Officer and confirmed COO Jessica Morris will present at the 2025 Virtual Investor Summit on March 11.

Read Also: What’s Going On With Alibaba Stock Thursday?

How To Buy TNXP Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Tonix Pharmaceuticals’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, TNXP has a 52-week high of $1,216.00 and a 52-week low of $6.76.